Document is current

Article History

Accepted: 5 November 2024

First Online: 3 December 2024

Declarations

:

: Lukas D. Landegger is supported by a Career Development Award from the American Society of Gene & Cell Therapy and the Children’s Tumor Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Society of Gene & Cell Therapy. The financial support of the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development, and the Christian Doppler Research Association is gratefully acknowledged.

: Lukas D. Landegger has received research funding from Decibel Therapeutics/Regeneron Pharmaceuticals and Amgen and has worked as an independent consultant for Akouos/Eli Lilly and Company, Conclave Capital, and Gerson Lehrman Group. Anselm J. Gadenstaetter and Paul E. Krumpoeck have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no original datasets were generated or analyzed during the current study. All data analyzed in this review are directly referenced to their original publications.

: Not applicable.

: AJG: methodology, validation, investigation, writing (original draft), visualization; PEK: methodology, validation, investigation, writing (review and editing); LDL: conceptualization, methodology, validation, investigation, writing (review and editing), supervision, project administration.